The assessment of depression in obstructive sleep apnea (OSA) is confounded by the overlap in symptoms between the disorders. However, previous analysis by our group has suggested that while some depressive symptoms tend to overlap with OSA (such as insomnia, lethargy, impaired concentration, psychomotor retardation) other, nonoverlapping symptoms appear more specific to depression (such as negative affect, anhedonia, and depressive cognitions). We sought to determine the value of such categorization of depressive symptoms in identifying clinical depression within OSA patient populations by examining the response of these two categories of depression symptoms to treatment of OSA by continuous positive airway pressure (CPAP). Three hundred fifty-seven unselected, CPAPnaïve OSA patients were treated with CPAP and followed over 12 weeks. Depressive symptoms were elicited before, during and at the end of this period using the Hamilton Rating Scale for Depression (HAM-D). Data were analyzed using latent growth curve modeling. At baseline, individuals reported proportionally more severe overlapping than nonoverlapping depressive symptoms. Both overlapping and nonoverlapping symptoms significantly decreased over time, but with a greater reduction in the severity of overlapping than nonoverlapping depressive symptoms. Moreover, greater CPAP use was associated with a faster rate of improvement in overlapping symptoms, but not in nonoverlapping symptoms. These findings suggest that nonoverlapping depressive symptoms may be useful discriminators of clinical depression amongst patients with untreated, symptomatic OSA.
Introduction
The frequency of depression in obstructive sleep apnea (OSA) has been reported to range from 7% to 63%, with between 37% and 44% of patients referred to a sleep clinic for OSA having at least mild depression [1] and as many as 24% of OSA patients seeing a psychiatrist for anxiety or depression [2] . By comparison, the prevalence of depression in the general adult population is 3% to 10% [3, 4] .
However, the diagnosis of depression in patients with OSA is confounded by the overlap of symptoms between the two disorders [5] because depressive symptoms are a common component of the clinical presentation of OSA [6] . Such symptoms include insomnia or loss of energy, weight gain, problems with concentration and psychomotor retardation [7] . By contrast, other depressive symptoms do not appear to overlap markedly with OSA including negative affect, anhedonia, and depressive cognitions (e.g. suicidal ideation, hopelessness) [7] .
Symptom overlap increases the risk of misdiagnosis of one condition for the other, leading to delayed or inappropriate treatment, increasing health burden. Depressive symptoms are a case in point, as they are widely prevalent and can have a number of underlying causes. Indeed, a criterion in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) for defining major depressive disorder is that "the episode is not attributable to the physiological effects of a substance or to another medical condition" [8] . In the case of OSA, depressive symptoms are commonly observed and misdiagnosis of OSA as depression is a significant problem [9] .
Meta-analysis suggests that measures with greater symptom overlap produce higher estimates of prevalence of depression in OSA [7] , creating the potential for over-or under-diagnosis. Further, symptom overlap is a challenge for studies examining the impact of treatment of OSA with continuous positive airway pressure (CPAP) on depressive symptomatology, making it difficult to determine what is being affected by CPAP treatment: OSA, depression, or both. Indeed, meta-analysis of the effects of treatment of OSA on depressive symptoms by Povitz et al. [10] has found considerable heterogeneity in symptomatic improvement between trials.
Moreover, few studies have examined which types of depressive symptoms are ameliorated with CPAP treatment [5, 11] and none whether there is a differential effect of CPAP on symptoms that overlap between depression and OSA and those that do not. The purpose of our study was to address this deficiency. We reasoned that if CPAP reduces only overlapping depressive symptoms, and does so in a dose-dependent manner, this would support the proposition that these overlapping symptoms are primarily the result of OSA and that the residual, nonoverlapping symptoms could be used to identify clinical depression amongst OSA patients.
Latent growth curve modeling (LGCM) can be used to assess each individual's pattern of change in symptoms over time, and the factors influencing change [12] . Hence, we planned to use LGCM to analyze the effect of CPAP therapy (assessed by (1) mean hourly usage per night and (2) good [≥4 hours use per night] vs. poor [<4 hours use per night] CPAP adherence) in ameliorating overlapping and nonoverlapping depressive symptoms, using the Hamilton Depression Rating Scale (HAM-D), in a 12-week, single-arm study. We hypothesized that: (1) the severity of overlapping depressive symptom scores would be higher than nonoverlapping depressive symptoms at baseline; (2) HAM-D total scores, and both overlapping and nonoverlapping symptom scores, would significantly decrease over time; (3) there would be a faster rate of decline of overlapping symptoms than nonoverlapping symptoms; and (4) greater CPAP use would be associated, in a dose-dependent manner, with greater decrease in HAM-D total scores, particularly for overlapping symptoms.
Methods

Protocol and participants
The Obstructive Sleep Apnea and Related Symptoms (OSARS) study was a longitudinal, 12-week, single-arm trial of CPAP. The study was approved by the Sir Charles Gairdner Hospital Research Ethics Committee and reciprocal approval was provided by UWA HREC (NHMRC 1031575). The study was registered with the Australian New Zealand Clinical Trials Registry: ACTRN12612001136897.
All participants provided written, informed consent. Participants, aged ≥18 years, were symptomatic patients referred between January 2014 and March 2016 to the Sleep Disorders Clinic at Sir Charles Gairdner Hospital for diagnosis of suspected OSA. Patients were assessed by an experienced sleep physician and a sleep study (polysomnogram [PSG]) arranged, depending on clinical features. Following PSG, the patient was reviewed by a physician and treatment options were discussed. Patients with OSA (AHI ≥ 5 events/hour), aged ≥18 years, local to the study site, and CPAP naïve who agreed to a CPAP trial were invited to participate in the study.
Exclusion criteria were: (1) AHI < 5 events/hr; (2) severe nocturnal desaturation (>2% of sleep time with an arterial oxygen saturation <85%); (3) central (non-obstructive) sleep apnea (≥50% of apneic/hypopneic events were non-obstructive); (4) predominantly Cheyne-Stokes respiration; (5) were currently on treatment for OSA (e.g. oral appliance); (6) likely non-OSA primary diagnosis, for example, symptomatic restless legs, insomnia, narcolepsy, delayed sleep phase disorder, sleep hypoventilation, neurological disorders; (7) presence of a disability that would prevent self-administration of the CPAP mask; (8) presence of severe medical morbidity that may compromise 3-month survival; (9) severe respiratory disease; (10) cerebrospinal fluid leak; (11) recent cranial surgery or trauma; (12) either English was a second language (ESL) or there was poor command of the English language; (13) meeting diagnostic criteria for Psychotic Mood Disorders or Substance use Disorders, as assessed by Structured Clinical Interview (SCID-I) at visit 1; (14) presence of significant cognitive deficits as assessed with the Mini Mental State Examination (MMSE) at visit 1 (cutoff < 24); (15) severe suicidality as measured on the Columbia Suicide Severity Rating Scale (CSSRS) at visit 1; (16) inability to attend study visits, or; (17) reported adjustment of dose of antidepressants or anxiolytics within the 12 weeks prior to the screening phase, or were to be adjusted during the term of treatment.
Patients were followed for 12 weeks, consisting of 5 clinic visits (visit 1, visit 1a, visit 2, visit 3, and visit 4), and any unscheduled sleep visits. Figure 1 outlines the measures gathered at each visit.
Measures
Demographic details
Data were collected on demographic (e.g. gender, birth date, marital status) and general health (e.g. smoking history, medical history, alcohol consumption) variables. Height (stadiometer) and weight measurements were completed at visit 1 and were used to calculate body mass index (BMI).
Overnight sleep study
All patients underwent a standard 12-channel PSG. PSGs were performed using the Compumedics Grael PSG system (Compumedics Ltd, Abbotsford, Australia) which recorded the following signals: C3/A2,C4/A1 F3/A2, F4/A1, O3/A2, and O4/ A1 electroencephalogram (EEG), bilateral electrooculogram (EOG), submental electromyogram (EMG), ECG, airflow at the nose and mouth, oximetry, chest and abdominal movement (inductance plethysmography), body position, sound intensity and bilateral tibial EMGs. Data were analyzed by Sleep Technologists using the American Academy of Sleep Medicine scoring criteria (AASM; 2012) to determine the apnea/hypopnea index (AHI), the standard metric of OSA severity. Apneas required a reduction in peak airflow signal excursion by ≥90% of pre-existing baseline that lasted for at least 10 seconds. Hypopneas required a reduction in peak airflow signal excursion by ≥30% of pre-existing baseline for at least 10 seconds, associated with either a ≥3% desaturation from pre-event baseline or arousal.
Hamilton Rating Scale for Depression
The HAM-D [13] is a 17-item measure that is used to examine the burden (type and magnitude) of depressive symptoms in the form of a semi-structured interview. The HAM-D is one of the most widely used outcome measures for depressive symptoms in clinical trials and has been shown to be a valid and reliable measure [14] . Nine items are scored on a 5-point scale ranging from 0 = not present to 4 = severe, and eight items are scored on a 3-point scale ranging from 0 = not present to 2 = severe. Scores range from 0 to 52, with higher scores representing more severe depressive symptoms. HAM-D severity classification cutoffs are: No depression (0-7); mild depression (8) (9) (10) (11) (12) (13) (14) (15) (16) ; moderate depression (17) (18) (19) (20) (21) (22) (23) , and; severe depression (≥24) [15] . The HAM-D was assessed at visits 1-4.
In a recent meta-analysis [16] , symptoms of depression in commonly used depression measures were categorized into symptoms that overlapped with OSA symptoms (OSArelated symptoms) or symptoms that did not overlap with OSA symptoms (nonoverlapping depressive symptoms). These categories were used to divide the HAM-D items. Overlapping symptoms (HAM-D items: 4, 5, 6, 13, and 14 [scored 0-2] and 7, 8, 10, and 11 [scored 0-4]), assess behavioral consequences (e.g. libido/ menstrual symptoms, psychomotor retardation, subjective tension/irritability, physical anxiety symptoms, for example, heart palpitations), sleep difficulties, loss of energy, and cognitive difficulties, whereas nonoverlapping symptoms (HAM-D items: 12, 16, and 17 [scored 0-2] and 1, 2, 3, 9, and 15 [scored 0-4]), assess agitation, loss of weight and appetite, negative affect (e.g. depressed mood), psychological symptoms of depression (e.g. helplessness, guilt, suicidal ideation, insight), anhedonia, and hypochondriasis.
Two, separate subscale scores were created for overlapping depressive symptoms (nine items; scored 0-26) and nonoverlapping depressive symptoms (eight items; scored 0-26). Overlapping symptoms and nonoverlapping symptom subscale scores were then converted to percentages to facilitate comparison.
CPAP device: usage and compliance
At visit 1, participants were provided with the same CPAP device (Resmed S9 Autoset-Australian Register or Therapeutic Goods [ARTG]), humidifier and tube with embedded heating circuit. A trained Sleep Scientist fitted an appropriate mask and instructed the participant how to use their CPAP device with heated humidification, in accordance with our standardized Sleep Disorders Clinic protocol. In particular, the patient used the device in automatic mode for the first week, to determine a fixed CPAP pressure (usually the 95th centile) for long-term use. Patients used the device in the fixed pressure mode for the remainder of the study. Data were downloaded from the CPAP device/smart card at each visit (including 1A and unscheduled visits). For the purposes of this study, CPAP use was defined as (1) the mean daily usage of CPAP in hours/per night and (2) the proportion of days that CPAP use was ≥4 hours per night (CPAP adherent according to clinical guidelines) [17] . Where there were missing data on CPAP use due to technical faults (N = 14 visits; nine [2.38%] participants), CPAP usage was based on the CPAP data that were available for the other visits. CPAP use data were not available for 20 participants who withdrew prior to their 2nd visit. 
Data analysis plan
Data screening and descriptive analyses were performed using SPSS 22.0 for Windows, IBM (2015). Latent growth curve modeling was performed using Mplus, version 8 [18] .
Latent Growth Curve Modeling
LGCM was performed to permit: (1) comparison of overlapping and nonoverlapping symptom scores at baseline; (2) comparison of the direction and rate of change of overlapping and nonoverlapping depressive symptoms over time; and (3) examination of the predictors (covariates: CPAP use and patient characteristics) that may influence the rate of change of overlapping and nonoverlapping depressive symptoms with treatment.
Analyses were conducted using Maximum Likelihood Estimation with robust standard errors (MLR), as this approach is robust to non-normality and is able to handle missing values [18] . Given this, we utilized all available data in our analysis, using this to deal with missing values. Different growth functional forms for trajectories were considered, including linear, quadratic, and logarithmic growth trends. Linear time was modeled as 0 (visit 1), 1 (visit 2), 2 (visit 3), 3 (visit 4); quadratic times as 0, 1, 2, 4. These different trajectories were modeled on the following outcome variables: (1) HAM-D total scores, (2) HAM-D overlapping symptom percentage scores, and (3) HAM-D nonoverlapping symptom percentage scores, across visits 1 to 4.
Overall model fit was evaluated using χ 2 . However, chisquare is sensitive to sample size [19] , thus we also report χ 2 /df, where <3 is taken to indicate reasonable fit [20] . Other indices were: Comparative Fit Index (CFI) [21] , Tucker-Lewis Index (TLI) [22] Root-Mean-Square Error of Approximation (RMSEA) [23] , Standardized Root Mean Squared Residual (SRMR) [24] , Akaike Information Criterion (AIC) [25] and parsimony ratio. The parsimony ratio represents the complexity of the model relative to the number of observed variables, where values closer to 1 indicate a more parsimonious model [26] . Recommended cutoffs for the fit indexes were: CFI: ≥.95, TLI: ≥.95, RMSEA: <.050, and SRMR: <.06020, and an AIC that is smaller was favored [25] . Significance was indicated by p < .05.
After finding a well-fitting growth model for the three different HAM-D scores, we evaluated the influence of specific covariates (baseline OSA severity [ To compare the baseline scores (intercept) and decline in symptoms over time (slope) between overlapping and nonoverlapping symptom proportion scores, chi-square tests were conducted by running the models (overlapping vs. nonoverlapping symptoms) in parallel. To examine if there was a significant difference in the intercepts or slopes, we conducted a comparison of the mean intercepts or mean slopes using Model Test in Mplus. A significant Wald test reveals that constraining the parameters to be equal indicates a significant difference between them.
Results
Of 1222 individuals screened, 562 were excluded, 73 declined participation, 161 were missed by researchers, and 56 did not attend a follow-up appointment after the initial physician assessment prior to visit 1. Three hundred seventy patients were further screened at visit 1, at which time a further 13 were excluded, leaving 357 who commenced the trial. Figure 2 shows the study flow.
Of the 357 who started the trial, 277 completed all four visits, with 80 dropping out prior to the final visit. All participants' data were analyzed regardless of whether or not they completed the trial (see Methods). Table 1 shows patient characteristics according to those who completed all visits compared with those who withdrew early. There were no significant differences between completers and non-completers in age, proportion of males, years of education, BMI, proportion taking anti-depressants, daytime sleepiness, or baseline OSA severity (AHI). Those who did not complete the trial were marginally more depressed at baseline, on the HAM-D Total score, but when HAM-D scores were divided into overlapping and nonoverlapping symptoms, only the latter were significantly different.
Descriptive statistics
The HAM-D scores (total, overlapping and nonoverlapping symptom scores) for each visit are in Tables 2 and 3 . We have also provided a breakdown, symptom by symptom in Supplementary Table S1 . The proportion of individuals in each HAM-D severity classification category at each visit are also in Table 2 . The majority of individuals scored in the mild or more severe depression range at visit 1, whereas, at visit 4, the majority scored in the no depression range. There were more individuals in the no depression range at visit 4, compared to visit 1 (p < .001, McNemar's test).
Building the growth models
HAM-D total scores
A quadratic fit (with the variance of the quadratic change term set to 0) was chosen as the best fitting single growth model for HAM-D total scores (Table 4) , based on a combination of fit indices, consistency of fit and interpretability. See Supplementary Table S2 for the different functional forms of the change models (e.g. linear, quadratic, and logarithmic growth trends) that were considered.
There was no significant relationship between total HAM-D scores at baseline (intercept term) and the decline (slope term) in depressive symptoms over time (r = −0.21, p = .115). At visit 1, the estimated average total HAM-D score was 10.98 points (intercept), which represents mild depression, but this varied significantly between individuals (revealed by a significant variance term). As indicated by the significant linear slope term, the average decrease in HAM-D total scores was 3.2 points per visit but this, too, varied significantly between participants. The combination of the linear and quadratic terms revealed an overall decrease from visit 1 to visit 4 (by 7.1 points 1 ), with a tendency for the slope of change to become shallower from visit 2 to 3 and again from visit 3 to 4.
Overlapping and nonoverlapping HAM-D symptom scores
Quadratic change models (with the variance of the quadratic change term set to 0) were the best-fitting, single-growth 1 Derived from the sum of the linear and quadratic terms, each multiplied by the time factor, that is, the difference between visit 1 (time = 0) and visit 4 (time = 3) = (3*−3.20) + (4*0.62) = −7.12. models for both the overlapping and nonoverlapping symptom percentage scores (Table 4 ; models 2 and 3). See Supplementary  Tables S3 and S4 for the different functional forms of change models that were considered. Figure 3 illustrates the trajectory of change in the overlapping and nonoverlapping HAM-D symptom percentage scores. There was no significant relationship between baseline, overlapping symptom scores and rate of overlapping symptom decline over time (r = −0.02; p = .910). By contrast, individuals who had more severe nonoverlapping symptoms at baseline had greater decrease in the severity of nonoverlapping symptoms over time (r = −0.27, p = .045).
At baseline, participants reported significantly greater percentage of overlapping than nonoverlapping symptoms (intercepts reported in Table 4 ): 30.15% versus 12.05%; Wald test = 817.95(1), p < .001, and differences in the rate of change (linear slope terms), with a greater reduction in overlapping than nonoverlapping symptoms from visits 1 to 4, with a reduction of nearly 10% per visit contrasting with less than 3% per visit: −9.64% versus −2.95% Wald test = 62.83(1), p < .001. There were also significant differences in the quadratic slopes, with a tendency for a greater slowing of the decrease in overlapping symptoms towards the end of the trial, than in nonoverlapping symptoms: 7.67% versus 1.15% Wald test = 29.19(1), p < .001.
Predictors of depression scores
HAM-D total scores
Individuals who were on antidepressant medication, with a higher BMI, and who used CPAP less during their treatment, had higher total HAM-D scores at baseline (intercept term). However, higher average CPAP use per night was also associated with a significantly faster drop in HAM-D total scores (slope), over time (Table 5 ; model 1).
Overlapping and nonoverlapping symptom scores
As for total HAM-D scores, individuals who were on antidepressant medication, or had higher BMI, reported higher overlapping percentage scores at visit 1, and higher average CPAP use per night was also associated with a faster drop in overlapping symptoms percentage scores (Table 5; model 2) .
Likewise, those on antidepressants, with higher BMI, and with lower average CPAP use reported higher nonoverlapping percentage symptom scores at visit 1. Further, younger age was associated both with higher baseline and a significantly faster drop in nonoverlapping percentage symptom scores. However, unlike total or overlapping HAM-D scores, CPAP use was not associated with rate of decline of nonoverlapping symptoms (Table 5 ; model 3), and this difference was significant (Diff = −0.45, SE Diff = 0.13, p = .001).
When proportion of nights with CPAP use ≥4 hours was entered as a predictor, instead of mean daily CPAP use (Supplementary Table S5 ), the results were substantively similar to those where the predictor was mean daily CPAP use.
Discussion
Many studies have investigated whether CPAP treatment for OSA treats depressive symptoms and have revealed an overall treatment effect [10] . The present study took a different approach. Its purpose was to determine, to the extent an individual complies with it, what is the effect of CPAP therapy on the rate, or slope, of change in that individual's depressive symptoms and is this a function of the type of depressive symptoms? Unlike studies designed to examine overall treatment effects (i.e. randomized control trials), these questions require analysis of differences in individual-by-individual use of therapy and the relationship between such differences and reduction in symptoms over time.
Thus, this study examined the effect of CPAP in ameliorating overlapping and nonoverlapping depressive symptoms using the HAM-D, in a 12-week, single arm study of a large cohort of CPAP naïve OSA patients drawn from a sleep clinic population. Our cohort is representative of the usual OSA patients seen in a sleep clinic and is unlikely to be biased by over-representation of depressive disorders. We have carefully also excluded potentially confounding conditions (e.g. central sleep breathing disorders) and other severe or complicating medical disorders (e.g. Duchenne muscular dystrophy) as well as significant complicating psychiatric conditions (e.g. substance abuse disorders) making these findings specific to OSA. Prior to treatment, 66.3% of individuals with OSA at baseline met the criteria for mild or more severe depression. As hypothesized, the severity of overlapping depressive symptoms was higher than nonoverlapping depressive symptoms before CPAP was implemented, consistent with the notion that OSA is a significant contributor to depressive symptomatology.
In terms of treatment response, and as predicted, both overlapping and nonoverlapping symptoms significantly decreased over time, but with a greater decrease in the severity of overlapping than nonoverlapping depressive symptoms. Hence, overlapping depressive symptoms appear to be more responsive to OSA treatment. CPAP is highly effective in treating OSA, and many OSA-related symptoms respond in a dose-dependent manner to CPAP use [27] . Likewise, greater CPAP use was associated with a faster rate of decrease in overlapping depressive symptoms, but not in nonoverlapping symptoms. This "dosedependent" relationship between CPAP use and improvement in overlapping depressive symptoms, and the finding that there were no baseline differences in overlapping symptoms between those who completed the trial and those who withdrew early, suggest this association may be causal.
Previously, just two other CPAP treatment studies have considered the impact of symptom overlap. Edwards et al. [5] found that all but one symptom (concentration item) in the Patient Health Questionnaire (nine-item PHQ) significantly decreased with CPAP. They argued that the concentration symptom, which is an OSA-related symptom, did not significantly reduce over time due to floor effects. Similarly, El-Sherbini et al. [28] found a significant decrease in HAM-D scores. When they then excluded four items which could be caused by OSA (items related to insomnia and fatigue), they still found a significant decrease in depressive symptoms over time, but to a lesser degree. However, they did not exclude other overlapping symptoms (e.g. loss of libido, psychomotor retardation), which may have confounded the results. Such symptoms were classified as overlapping in our study. Despite this difference, the overall effects reported by El-Sherbini et al. [28] are supportive of our findings.
While, as stated earlier, our primary intent was to examine the effect of CPAP therapy on slopes of change in individuals' depressive symptoms and whether this was a function of the type of depressive symptoms, we did observe a substantial decrease in overall depressive symptomatology. The proportion with symptoms meeting criteria for mild or more severe depression decreased from 66.3% to 23.9% over the course of the study. Without a control arm to the study, it is possible that these overall responses were the result of regression to the mean [29] and/ or placebo/Hawthorne effects [30] , or random error. Although the overall magnitude of change in symptoms could be influenced by placebo effects, a placebo effect would not explain the different patterns of change between the two categories of depression symptoms, even in the context of baseline differences between completers and non-completers. While those who experience a stronger expectation of benefit (i.e. a placebo effect) may use treatment more and thereby gain more benefit, it seems unlikely that such a placebo effect would only pertain to overlapping symptoms. Notably, after CPAP treatment, there was a substantial difference in symptomatology between those whose depressive symptoms responded to the therapy and those whose symptoms did not. Persistent symptoms, where OSA has been factored out by CPAP therapy, suggest that OSA is less strongly implicated in them. Where symptoms persisted, they were more commonly of the non-overlapping variety, consistent with our hypothesis. Moreover, the large numbers of patients studied makes it particularly unlikely that this is a chance finding due to random factors or to regression to the mean because, if symptoms improved unrelated to OSA treatment but rather to the passage of time, then we would not expect a relationship between CPAP use and OSA symptom improvement in either overlapping or nonoverlapping symptoms.
One further possibility is that the effects found were a consequence of overlapping symptoms being more common in depression, regardless of whether or not OSA is also present. It is an interesting empirical question as to whether or not the symptoms of depression that overlap with OSA are also more common than nonoverlapping symptoms in people with depression but without OSA, and we need studies that explore this possibility. However, this does not bear on the differential response to CPAP treatment use of overlapping and nonoverlapping symptoms.
Despite the absence of a treatment control condition, the most parsimonious explanation of our results is that CPAP treats overlapping depressive symptoms, which may suggest that CPAP is treating OSA, rather than depression, per se. Importantly, as the nonoverlapping depressive symptoms are less responsive to CPAP, do not improve as much as overlapping symptoms, and seem to be associated with early withdrawal from treatment, additional types of treatment strategies, such as psychological interventions or antidepressant medication, may be required further to ameliorate symptom severity and improve CPAP treatment compliance [31] . Furthermore, these nonoverlapping symptoms may well be useful discriminators of true clinical depression amongst patients with OSA, and may help in the design of an OSA-specific depression scale.
Our findings show that severity of OSA, as assessed by AHI, was unrelated to severity of depressive symptoms. However, the lack of association of AHI with a range of clinical features is well established (e.g. daytime sleepiness [32] and cognitive deficits [33] ) and yet there is good evidence that treating OSA improves these very symptoms [33] [34] [35] . The mechanism may not be evident because all the physiological consequences of OSA have not yet been investigated, for example, there may be relationships between OSA and depression due to OSA-related inflammation [36] . We note that AHI is a single, often poor, summary measure of OSA severity and unlikely to capture many of the important underlying pathophysiological processes that may drive disease or its psychological consequences. However, the metric reliably identifies the presence of OSA, as it is a measure of the fundamental characteristic that defines the condition: the presence of repetitive partial or complete upper airway obstructive events during sleep.
Our study focused on individual depressive symptoms, categorized a priori (top-down) into overlapping and nonoverlapping sets, and their differential change over time in response to treatment. We have used this to approach to disentangle depression as an independent pathology from depressive symptomatology resulting from disrupted sleep. Another method might be to take a symptom-based approach that categorizes depression symptoms inductively (bottom up), so as to inform our understanding of the phenomenology and heterogeneity of depression in OSA. One such approach is Latent Profile Analysis (LPA), which assumes there are distinct patterns of observed scores (indicators) and that individuals can be grouped into a small number of subtypes/phenotypes based on those patterns of scores [37, 38] . LPA has been used in understanding the phenomenology of depression in Parkinson's disease and type-2 diabetes [39, 40] but not, to our knowledge, in OSA. Overall, this study shows that overlapping depressive symptoms are more severely expressed in OSA than nonoverlapping symptoms, that both categories decrease with CPAP treatment, but that only overlapping symptoms do so as a function of amount of CPAP use. These findings suggest that overlapping depressive symptoms are primarily attributable to untreated OSA. It is unclear if the more desultory decrease in nonoverlapping symptoms is a genuine improvement. Regardless, these data add further support to our previous work indicating that nonoverlapping symptoms could be useful discriminators of true clinical depression amongst individuals with OSA.
